JAHA:心梗PCI治疗后心绞痛的治疗管理

2017-10-20 MedSci MedSci原创

心绞痛严重影响着经皮冠脉介入治疗(PCI)后心梗患者的生活质量,而PCI后心绞痛的管理尚属未知。本研究纳入了TRANSLATE‐ACS临床试验中2010年至2012年233家医院里的接受PCI治疗的心梗住院病人。根据患者自我描述的心绞痛症状,本研究整理了PCI治疗6周后的心绞痛的分型及抗心绞痛的药物治疗管理。最终共纳入了10870名接受PCI治疗的心梗患者,有3190(29.3%)名患者在PCI治

心绞痛严重影响着经皮冠脉介入治疗(PCI)后心梗患者的生活质量,而PCI后心绞痛的管理尚属未知。

本研究纳入了2010-12年间TRANSLATE‐ACS临床试验中,于233家医院接受PCI治疗的心梗住院病人。根据患者自我描述的心绞痛症状,本研究整理了PCI治疗6周后的心绞痛的分型及抗心绞痛的药物治疗管理。最终共纳入了10870名接受PCI治疗的心梗患者,有3190(29.3%)名患者在PCI治疗后6周出现心绞痛,其中,有658名患者的心绞痛症状是每日或者每周出现的,2532名患者出现的频率为每月1-2次。此外,在PCI治疗后6周出现有心绞痛的患者中,有2936名(92%)患者接受了β受体阻滞剂治疗,仅有743名患者接受了其他的抗心绞痛治疗。在PCI治疗后一年,仍有1056名(33.1%)患者有持续性心绞痛症状,其中有31.2%的患者在过去的一年中没有接受β受体阻滞剂治疗。

研究结果显示,心梗患者在接受PCI治疗后6周,大约有三分之一会出现心绞痛症状,并有相当一部分患者有持续性心绞痛,其中大部分患者均有接受β受体阻滞剂治疗。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2030093, encodeId=1fe02030093fd, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Mar 31 09:52:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267563, encodeId=a99b126e563af, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Oct 22 00:52:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254605, encodeId=a46e25460589, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Oct 20 13:50:18 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254562, encodeId=e446254562d1, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Fri Oct 20 10:39:38 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2030093, encodeId=1fe02030093fd, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Mar 31 09:52:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267563, encodeId=a99b126e563af, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Oct 22 00:52:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254605, encodeId=a46e25460589, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Oct 20 13:50:18 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254562, encodeId=e446254562d1, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Fri Oct 20 10:39:38 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
    2017-10-22 zhaohui6731
  3. [GetPortalCommentsPageByObjectIdResponse(id=2030093, encodeId=1fe02030093fd, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Mar 31 09:52:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267563, encodeId=a99b126e563af, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Oct 22 00:52:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254605, encodeId=a46e25460589, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Oct 20 13:50:18 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254562, encodeId=e446254562d1, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Fri Oct 20 10:39:38 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
    2017-10-20 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2030093, encodeId=1fe02030093fd, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Mar 31 09:52:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267563, encodeId=a99b126e563af, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Oct 22 00:52:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254605, encodeId=a46e25460589, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Oct 20 13:50:18 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254562, encodeId=e446254562d1, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Fri Oct 20 10:39:38 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
    2017-10-20 Y—xianghai

    学习了新知识

    0

相关资讯

JACC:Brugada综合征的ICD治疗研究

Brugada综合征(BrS)患者是否需要接受植入型心律转复式除颤器(ICD)治疗尚存在争议。近日,在国际心血管权威杂志JACC上发表了一篇旨在评估BrS患者接受ICD治疗长期预后的临床研究。本研究纳入了370例Brugada综合征患者,其中有104例(28.1%)患者接受了ICD治疗,患者的年龄为43 ± 14岁,男性占74%。对患者的长期卒中和其他并发症进行随访评估。在104例接受ICD治疗患

JACC:心脏结构位点突变在房颤发生中起重要作用

全基因组关联分析(GWAS)已经发现与房颤相关的>30个基因位点的突变,其中就包括肌节基因MYH6 和MYL4的罕见突变位点.本研究旨在利用GWAS和心电图检测技术探索与房颤相关新的位点突变。本研究利用冰岛的全基因组数据对14255名房颤患者和374939名正常对照进行GWAS分析,并在2002名非冰岛患者和12324名正常对照上对新发位点进行验证。然而,在62974名研究对象上利用心电图技术检测

Psychot & Psychos:抗抑郁药物的又一个神奇作用

抗抑郁药通常是处方药,但他们的长期对身体的健康影响却存在争议。抗抑郁药破坏多个自适应过程的生化调节,有可能增加死亡率。然而,许多抗抑郁药也有抗血管的特性,可以有效地治疗心血管疾病。

JACC:去肾脏交感神经可改善心衰患者心功能

心衰患者的交感神经持续兴奋可能造成心肌细胞损伤、心肌纤维化和左室功能不全。本研究的目的是为了评估肾脏神经射频消融(RF-RDN)对心衰患者的影响,并且对肾脏交感神经与利尿肽代谢相关性进行评估。本研究对自发性高血压大鼠(SHR)和正常血压大鼠(WKY)进行45min的冠脉结扎和再灌注,随访12周。再灌注后4周,对SHR和WKY进行RF-RDN或者假手术。相比于假手术组大鼠,射频消融组的大鼠左室射血分

JACC:PCSK9可作为心衰患者预后的预测因子

前蛋白转化酶枯草溶菌素9(PCSK9)可以靶向结合低密度脂蛋白受体(LDLR),防止其再循环利用。因此,PCSK9可作为动脉粥样硬化的预测因子和药物的靶点。本研究的目的是评估PCSK9-LDLR对心衰患者是否有降低动脉粥样硬化风险的作用。本研究纳入的是BIOSTAT-CHF临床试验中的心衰患者,主要终点事件是全因死亡率、心衰的复合死亡率和心衰的住院率。最终共纳入了2174名心衰患者(平均年龄为68

JACC:脂蛋白的糖基化水平会影响T2DM患者的冠心病发生

脂蛋白的非酶糖基化作用在糖尿病患者血管并发症的发生过程中起到重要作用。近日,在国际心血管权威杂志JACC上发表了一篇旨在评估2型糖尿病(T2DM)患者的脂蛋白(apo)A-IV是否存在糖基化,并且apoA-IV的糖基化是否与冠心病(CAD)的发生有关的临床研究。本研究纳入了204名不伴有CAD的T2DM患者(第一组),515名伴有CAD的T2DM患者(第二组)和176名正常对照。apoA-IV是从